Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Hyperfine partnership aims to increase brain scans

While annual procedures like mammograms and colonoscopies can detect early signs of cancer, routine scanning for brain disease remains less common. A Guilford company’s new...

| By Kelley Gipson

Biohaven names new board chairman, CFO

The board of directors of Biohaven Pharmaceuticals recently elected CEO Vlad Coric to the role of board chairman, following the retirement of Declan Doogan. Meanwhile, Matthew Buten will...

| By Kelley Gipson

FDA approves Pfizer COVID-19 oral antiviral

The FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate...

| By Kelley Gipson

BioXcel begins Phase 3 study re Alzheimer’s disease

A potential treatment for agitation in patients suffering from Alzheimer’s disease is moving closer to market. New Haven-based BioXcel Therapeutics has announced the start of its Phase...

| By Kelley Gipson

Nasdaq biotech index adds Guilford’s Quantum-Si

The Nasdaq Biotechnology Index now includes Guilford biotech firm Quantum-Si. The Biotechnology Index tracks the performance of a select group of biotechnology or pharmaceutical securities. Nasdaq indexed...

| By Kelley Gipson

InveniAI and Kyowa Kirin expand partnership

InveniAI® and Kyowa Kirin have expanded their longstanding relationship with a new, multiple drug discovery agreement. The collaboration will provide Kyowa Kirin with access to InveniAI’s...

| By Kelley Gipson

Guilford COVID home-test firm Detect names CEO

Hugo Barra, formerly an executive at social-media leader Facebook and web-search giant Google, has been named chief executive officer of Detect, a Covid-19 testing startup. The company...

| By Kelley Gipson

XVIVO COVID animation goes viral!

The Vaccine Makers Project, a program of the Vaccine Education Center at Children’s Hospital of Philadelphia (VEC@CHOP) and Medical History Pictures (MHP) partnered up again...

| By Kelley Gipson

Pfizer confirms its pill effective vs. omicron

Pfizer reports its experimental pill to treat COVID-19 appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed...